시장보고서
상품코드
2023525

마이크로바이옴 분석 시장 분석 및 예측(-2035년) : 유형, 제품 유형, 서비스, 기술, 구성 요소, 용도, 프로세스, 최종사용자

Microbiome Analytics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User

발행일: | 리서치사: 구분자 Global Insight Services | 페이지 정보: 영문 350 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 4,750 금액 안내 화살표 ₩ 7,145,000
PDF & Excel (Site License) help
PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.
US $ 5,750 금액 안내 화살표 ₩ 8,650,000
PDF & Excel (Enterprise License) help
PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 6,750 금액 안내 화살표 ₩ 10,154,000
카드담기
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 마이크로바이옴 해석 시장은 2025년 14억 달러에서 2035년까지 38억 달러로 성장하며, CAGR은 10.9%에 달할 것으로 예측됩니다. 마이크로바이옴 분석 시장은 2026년까지 연간 2,500만 건 이상의 샘플을 처리할 것으로 예측됩니다. 그 중 55%는 헬스케어 분야가 차지하고 있습니다. 북미가 43%의 점유율로 1위를 차지하고 있습니다. AI를 활용한 분석 플랫폼은 CAGR 35%로 성장하고 있습니다. 조사에서 장내 미생물 연구가 60%를 차지합니다. 2030년까지 마이크로바이옴 데이터에 기반한 맞춤형 영양 솔루션은 전 세계 8,000만 명의 사용자에게 제공될 것으로 예상됩니다.

마이크로바이옴이 인간의 건강과 질병 치료에 미치는 역할을 강조하는 연구가 증가함에 따라 치료 분야가 성장을 주도하고 있습니다. 제약회사와 생명공학 기업은 다양한 질병에 대한 혁신적인 솔루션을 개발하기 위해 마이크로바이옴 기반 치료법에 투자하고 있습니다. 인체내 미생물 간의 상호작용에 대한 이해가 깊어짐에 따라 맞춤형 의료의 발전이 촉진되고 있습니다. 연구기관 역시 마이크로바이옴 분석에 기반한 표적치료제 개발에 집중하고 있습니다. 첨단 치료 솔루션에 대한 수요가 증가함에 따라 마이크로바이옴 분석은 헬스케어 산업 전반의 신약 개발 및 개발 과정에서 필수적인 툴이 되고 있습니다.

메타게놈 시퀀싱은 미생물 군집에 대한 포괄적인 지식을 제공할 수 있으며, 빠르게 확산되고 있습니다. 이 기술을 통해 환경 시료의 유전물질을 정밀하게 분석하여 미생물을 정확하게 식별할 수 있습니다. 시퀀싱 기술과 데이터 분석 툴의 지속적인 발전으로 효율성과 정확성이 향상되고 있습니다. 마이크로바이옴 과학에 대한 조사가 확대됨에 따라 메타게놈 시퀀싱은 복잡한 생물계를 이해하는 데 필수적인 기술이 되고 있습니다. 헬스케어, 농업, 환경 모니터링 분야에서의 적용이 강력한 성장을 주도하고 있으며, 다양한 산업 분야에서 채택이 확대되고 있습니다.

지역별 개요

2025년 기준, 북미는 강력한 연구 역량과 헬스케어 및 제약 분야에서의 채용 확대로 인해 마이크로바이옴 분석 시장을 주도할 것으로 예상됩니다. 미국은 질병 진단 및 신약개발을 위한 마이크로바이옴 연구에 대한 막대한 투자로 시장을 선도하고 있습니다. 첨단 연구소와 생명공학 기업의 존재가 혁신을 가속화하고 있습니다. 맞춤형 의료에 대한 수요 증가와 장 건강에 대한 인식이 높아진 것도 채용을 더욱 촉진하고 있습니다. 또한 정부의 재정 지원과 임상 연구 구상이 성장을 지원하고 있으며, 북미는 가장 높은 성장률을 보이는 지역 시장으로 꼽히고 있습니다.

아시아태평양은 헬스케어 분야에 대한 투자 확대와 연구 활동의 활성화로 인해 가장 빠르게 성장하는 지역이 될 것으로 예상됩니다. 중국, 인도 등의 국가들은 마이크로바이옴에 기반한 치료법과 진단법에 집중하고 있습니다. 예방의학에 대한 인식이 높아지고 바이오테크놀러지 분야가 확대되면서 수요가 증가하고 있습니다. 또한 정부의 지원과 의료 인프라의 개선으로 도입이 가속화되고 있습니다. 연구기관과 업계 관계자들의 협력 강화는 성장을 더욱 촉진하고 있으며, 아시아태평양은 세계에서 가장 빠르게 성장하는 지역으로 자리매김하고 있습니다.

주요 동향 및 촉진요인

마이크로바이옴 기반 헬스케어 솔루션에 대한 관심이 높아지고 있다:

마이크로바이옴 분석 시장은 마이크로바이옴 기반 헬스케어 솔루션에 대한 관심이 높아지면서 성장하고 있습니다. 연구에 따르면 마이크로바이옴은 면역, 소화, 질병 발병에 영향을 미치며 인간의 건강에 중요한 역할을 하는 것으로 나타났습니다. 의료진은 마이크로바이옴 데이터를 활용하여 개인 맞춤형 치료법과 진단법을 개발하고 있습니다. 만성질환의 유병률 증가는 고급 분석 툴에 대한 수요를 더욱 촉진하고 있습니다. 정밀의료가 대중화되면서 마이크로바이옴 분석은 환자 고유의 건강 상태를 이해하고 치료 효과를 향상시키는 데 중요한 요소로 자리 잡고 있습니다.

시퀀싱 및 생물정보학 기술의 발전:

시퀀싱과 바이오인포매틱스의 기술 발전이 시장 성장을 주도하고 있습니다. 차세대 염기서열분석(NGS) 기술을 통해 미생물 군집에 대한 상세한 분석을 빠르고 정밀하게 수행할 수 있게 되었습니다. 바이오인포매틱스 툴의 개선으로 대규모 마이크로바이옴 데이터세트를 효율적으로 처리하고 해석할 수 있게 되었습니다. 클라우드 기반 플랫폼은 데이터에 대한 접근성을 높이고, 연구자 간의 협력을 촉진하고 있습니다. 계산생물학의 지속적인 혁신으로 마이크로바이옴의 상호 작용에 대한 예측 모델링이 향상되고 있습니다. 이러한 기술이 발전함에 따라 마이크로바이옴 분석은 헬스케어, 제약, 영양 산업 각 분야로 확대될 것으로 예상됩니다.

목차

제1장 개요

제2장 시장 하이라이트

제3장 시장 역학

제4장 부문 분석

제5장 지역별 분석

제6장 시장 전략

제7장 경쟁 정보

제8장 기업 개요

제9장 Global Insight Services 소개

KSA

The global microbiome analytics market is projected to grow from $1.4 billion in 2025 to $3.8 billion by 2035, at a compound annual growth rate (CAGR) of 10.9%. The microbiome analytics market is projected to process over 25 million samples annually by 2026. Healthcare applications account for 55% of usage. North America leads with 43% share. AI-driven analytics platforms are growing at 35% CAGR. Gut microbiome studies represent 60% of research focus. By 2030, personalized nutrition solutions based on microbiome data are expected to reach 80 million users globally.

Therapeutics is leading growth as increasing research highlights the role of microbiomes in human health and disease treatment. Pharmaceutical and biotechnology companies are investing in microbiome-based therapies to develop innovative solutions for various conditions. The growing understanding of microbial interactions within the human body is supporting advancements in personalized medicine. Research institutions are also focusing on developing targeted treatments based on microbiome analysis. As demand for advanced therapeutic solutions increases, microbiome analytics is becoming a critical tool in drug discovery and development processes across the healthcare industry.

Market Segmentation
TypeGut Microbiome, Oral Microbiome, Skin Microbiome, Vaginal Microbiome, Others
ProductInstruments, Kits and Reagents, Software, Others
ServicesSequencing Services, Data Analysis Services, Consulting Services, Others
Technology16S rRNA Sequencing, Metagenomic Sequencing, Metatranscriptomic Sequencing, Others
ComponentHardware, Software, Services, Others
ApplicationTherapeutics, Diagnostics, Research and Development, Others
ProcessSample Preparation, Sequencing, Data Analysis, Others
End UserPharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Others

Metagenomic sequencing is growing rapidly due to its ability to provide comprehensive insights into microbial communities. This technology allows detailed analysis of genetic material from environmental samples, enabling accurate identification of microorganisms. Continuous advancements in sequencing techniques and data analysis tools are improving efficiency and accuracy. As research in microbiome science expands, metagenomic sequencing is becoming an essential technology for understanding complex biological systems. Its applications in healthcare, agriculture, and environmental monitoring are driving strong growth and increasing adoption across multiple industries.

Geographical Overview

North America dominates the microbiome analytics market in 2025 due to strong research capabilities and increasing adoption in healthcare and pharmaceuticals. The United States leads with significant investments in microbiome research for disease diagnosis and drug development. The presence of advanced laboratories and biotechnology companies accelerates innovation. Growing demand for personalized medicine and increasing awareness about gut health further drive adoption. Additionally, government funding and clinical research initiatives support growth, making North America the highest growing regional market.

Asia-Pacific is expected to be the fastest growing region due to rising healthcare investments and increasing research activities. Countries like China and India are focusing on microbiome-based therapies and diagnostics. Growing awareness about preventive healthcare and expanding biotechnology sector drive demand. Additionally, government support and improving healthcare infrastructure accelerate adoption. Increasing collaborations between research institutions and industry players further boost growth, making Asia-Pacific the fastest growing region globally.

Key Trends and Drivers

Growing Interest in Microbiome-Based Healthcare Solutions:

The Microbiome Analytics Market is growing due to increasing interest in microbiome-based healthcare solutions. Research has shown that microbiomes play a critical role in human health, influencing immunity, digestion, and disease development. Healthcare providers are leveraging microbiome data to develop personalized treatments and diagnostics. The rising prevalence of chronic diseases is further driving demand for advanced analytical tools. As precision medicine gains traction, microbiome analytics is becoming a key component in understanding patient-specific health conditions and improving treatment effectiveness.

Advancements in Sequencing and Bioinformatics Technologies:

Technological advancements in sequencing and bioinformatics are driving market growth. Next-generation sequencing (NGS) technologies enable detailed analysis of microbial communities at high speed and accuracy. Improved bioinformatics tools allow efficient processing and interpretation of large microbiome datasets. Cloud-based platforms are enhancing data accessibility and collaboration among researchers. Continuous innovation in computational biology is improving predictive modeling of microbiome interactions. As these technologies advance, microbiome analytics is expected to expand across healthcare, pharmaceuticals, and nutrition industries.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Strategic Recommendations
  • 1.5 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Technologies Landscape
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Gut Microbiome
    • 4.1.2 Oral Microbiome
    • 4.1.3 Skin Microbiome
    • 4.1.4 Vaginal Microbiome
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Instruments
    • 4.2.2 Kits and Reagents
    • 4.2.3 Software
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Sequencing Services
    • 4.3.2 Data Analysis Services
    • 4.3.3 Consulting Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 16S rRNA Sequencing
    • 4.4.2 Metagenomic Sequencing
    • 4.4.3 Metatranscriptomic Sequencing
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Therapeutics
    • 4.6.2 Diagnostics
    • 4.6.3 R&D
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Companies
    • 4.7.3 Academic & Research Institutes
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Sample Preparation
    • 4.8.2 Sequencing
    • 4.8.3 Data Analysis
    • 4.8.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Process
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Process
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Process
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Process
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Process
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Process
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Process
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Process
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Process
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Process
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Process
    • 5.4.6 Rest of APAC
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Process
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Process
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Process
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Process
    • 5.5.4 Italy
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Process
    • 5.5.5 Rest of Europe
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Process
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Process
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Process
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Process
    • 5.6.4 Rest of MEA
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Process

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Illumina
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 QIAGEN
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bio-Rad Laboratories
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Agilent Technologies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Becton Dickinson
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Danaher Corporation
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 PerkinElmer
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 F. Hoffmann-La Roche
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Eurofins Scientific
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Charles River Laboratories
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Merck KGaA
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Novogene
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Zymo Research
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Second Genome
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 CosmosID
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Enterome
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Microbiome Insights
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 BiomeSense
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Diversigen
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기